Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Noopur Raje, Kenneth C. Anderson, Hermann Einsele, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 73

Showing 26-50 of 73 citing articles:

Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations
Panos Arvanitis, Andreas Tziotis, Spyridon Papadimatos, et al.
Current Oncology (2025) Vol. 32, Iss. 4, pp. 198-198
Open Access
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
Ricardo Parrondo, Sikander Ailawadhi, Claudio Cerchione
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Current status of bispecific antibodies and CAR-T therapies in multiple myeloma
Wojciech Szlasa, Jarosław Dybko
International Immunopharmacology (2024) Vol. 134, pp. 112043-112043
Closed Access | Times Cited: 3
Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies
Hind Rafei, Katayoun Rezvani
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 764-766
Closed Access | Times Cited: 3
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
Darren Pan, Joshua Richter
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 6, pp. 237-245
Closed Access | Times Cited: 3
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them
Matthew Rees, Shaji Kumar
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 65, Iss. 3, pp. 287-300
Closed Access | Times Cited: 7
SEETrials: Leveraging Large Language Models for Safety and Efficacy Extraction in Oncology Clinical Trials
Kyeryoung Lee, Hunki Paek, Liang‐Chin Huang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma
Alexander M. Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials
Xin Wang, Ailin Zhao, Jinbing Zhu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Seetrials: Leveraging Large Language Models for Safety and Efficacy Extraction in Oncology Clinical Trials
Kyeryoung Lee, Hunki Paek, Liang‐Chin Huang, et al.
(2024)
Closed Access | Times Cited: 2
Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
Danilo De Novellis, Raffaele Fontana, Bianca Serio, et al.
Cancer Medicine (2024) Vol. 13, Iss. 14
Open Access | Times Cited: 2
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Noopur Raje, Adam D. Cohen, Krina K. Patel, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 6, pp. 350-357
Closed Access | Times Cited: 1
Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study
Donna Catamero, Patricia Blázquez Benito, Samantha Shenoy, et al.
Seminars in Oncology Nursing (2024) Vol. 40, Iss. 3, pp. 151621-151621
Open Access | Times Cited: 1
How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy
James A. Davis, Mary McGann, Jessica Marini, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 6, pp. 335-338
Open Access | Times Cited: 1
Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient
Panos Arvanitis, Dimitrios Farmakiotis, Ari Pelcovits
Current Oncology (2024) Vol. 31, Iss. 5, pp. 2670-2678
Open Access | Times Cited: 1
Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy
Moran Wang, Chaofan Wang, Jun Deng, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 6, pp. 216-216
Open Access | Times Cited: 1
Multiple myeloma and infections in the era of novel treatment modalities
Mobil Akhmedov, P. A. Zeynalovа, А. А. Феденко
Leukemia Research (2024) Vol. 143, pp. 107544-107544
Closed Access | Times Cited: 1
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
Andrew J. Yee
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement
Marise R. Heerma van Voss, Remco J. Molenaar, Charlotte L.B.M. Korst, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 9, pp. 889-901
Open Access | Times Cited: 1
SEETrials: Leveraging Large Language Models for Safety and Efficacy Extraction in Oncology Clinical Trials
Kyeryoung Lee, Hunki Paek, Liang‐Chin Huang, et al.
Informatics in Medicine Unlocked (2024) Vol. 50, pp. 101589-101589
Open Access | Times Cited: 1
The impact of institutional measures on optimal use of intravenous immunoglobulin
Jean‐Nicolas Champagne, Antoine Desîlets, Guillaume Roy, et al.
Transfusion (2024)
Open Access | Times Cited: 1
Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement
Guido Lancman, Kevin Song, Darrell White, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
Tarek H. Mouhieddine, Bruno Almeida Costa, Joshua Richter
Seminars in Hematology (2024)
Closed Access | Times Cited: 1
Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma
Christine Riedhammer, J. Düll, Christian Kestler, et al.
Annals of Hematology (2023) Vol. 103, Iss. 4, pp. 1327-1332
Open Access | Times Cited: 3
Understanding Infection Risk with Anti-BCMA Bispecific Antibodies
Alfred L. Garfall, Edward A. Stadtmauer
Blood Cancer Discovery (2023) Vol. 4, Iss. 6, pp. 427-429
Open Access | Times Cited: 2

Scroll to top